News and Press

Press releases

Diagonal Bio appoints Karin Wehlin as new CEO

Regulatory

Diagonal Bio AB (publ.) (“Diagonal Bio” or “the Company”) is pleased to announce that the Board of Directors has appointed Karin Wehlin as Chief Executive Officer (CEO) of Diagonal Bio. Karin Wehlin is currently Diagonal Bio’s interim CEO.

Read more

Notice to attend the extraordinary general meeting of Diagonal Bio AB

Regulatory

Shareholders in Diagonal Bio AB, 559248-8984, are hereby invited to attend an extraordinary general meeting on Tuesday, 2nd of April, 2024, at 13:00 CET at The Spark, conference room 10, Medicon Village, Scheeletorget 1 Lund.

Read more

The Board of Directors decides on a preferential rights issue of units in order to finance future development

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. The Board of Directors of Diagonal Bio AB (“Diagonal Bio” or the “Company”) has today, on February 28, 2024, resolved to carry out an issue of units (the “Rights Issue”) consisting of shares and free warrants of series TO 1 (“TO 1”), with preferential right for the Company’s existing shareholders. The decision is subject to approval at the Extraordinary General Meeting scheduled to be held on April 2, 2024. The Rights Issue is conditional upon the limits of the share capital and number of shares in the Articles of Association being amended and the reduction of the share capital being resolved in accordance with the Board of Directors’ proposal to the Extraordinary General Meeting. The issue volume initially amounts to a maximum of approximately SEK 32 million before transaction related costs. Upon full subscription of the Rights Issue and full utilization of issued TO 1 at the highest subscription price, the Company will receive an additional approximately SEK 9.5 million before transaction related costs. The decision on the Rights Issue is secured in writing by members of the Board, management, certain existing owners and external investors to a total of approximately 56.4 percent (corresponding to approximately SEK 18 million) through pre-subscription and guarantee commitments. To finance the operations until the proceeds from the Rights Issue are received by the Company, Diagonal Bio has also raised a bridge loan of approximately SEK 4 million. A prospectus, containing a detailed description of the offer and operations, will be published no later than when the subscription period for the Rights Issue begins. Notice of the Extraordinary General Meeting will be published in a separate press release.

Read more

Diagonal Bio AB Year-end Report 2023

Regulatory

“Looking back at 2023, I am proud to point out the significant steps we have made in our development, including the key achievements such as the CE-marking of LAMPlify® according to Low Voltage Directive (LVD) 2006/95/ EC. A highlight of our fourth quarter was the commencement of LAMPlify® commercialisation.” says, Karin Wehlin, interim CEO Diagonal Bio AB.

Read more

Diagonal Bio AB has signed a distribution agreement with Techtum Lab AB

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has signed a distribution agreement with Techtum Lab AB (“Techtum Lab”). Techtum Lab is granted the rights to distribute Diagonal Bio’s analytical instrument, LAMPlify®, in Sweden until May 30, 2025, with an option for a 12-month renewal. This collaboration was initiated by a first critical milestone in the pilot study which started in November 2023.

Read more